Elan Corporation, plc (ADR) - ELN - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Elan Corporation, plc (ADR) - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
ELN	New York	2834	http://www.elan.com	12.47 +0.11
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Elan Corporation, plc (ADR) Wohl & Fruchter LLP and Pomerantz Grossman Hufford Dahlstrom & Gross LLP File Consolidated Class Action Complaint on Behalf of Investors in Elan Corporation, plc Alleging Insider Trading by S.A.C. Capital Advisors, L.P. and Affiliates - May 24th, 2013 7:15 pm Elan Rejects Royalty Offer Again - May 24th, 2013 1:30 pm InPlay: Elan: Royalty Pharma discloses acceptance levels of original offer for Elan - May 24th, 2013 5:10 am Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements - May 24th, 2013 5:04 am Elan Board Rejects Royalty Pharma's Latest Offer - May 23rd, 2013 9:14 pm Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 - May 23rd, 2013 2:27 pm 3 Merger and Acquisitions Stock Stories For a Thursday Appraisal - May 23rd, 2013 12:31 pm Alkermes Reports Earnings for Q4 - May 23rd, 2013 11:25 am Elan board rejects Royalty Pharma's revised tender offer - May 23rd, 2013 9:41 am Elan Corporation, plc’s Board of Directors Unanimously Reject Royalty Pharma’s Revised Tender Offer - May 23rd, 2013 9:40 am Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share - May 23rd, 2013 4:31 am Value Investor Seth Klarman's Shakeups - May 22nd, 2013 2:08 pm Alkermes Earnings Seen Rising, But Sales Uncertain - May 22nd, 2013 1:54 pm When Savvy Dealmaking Borders on Reckless Spending - May 21st, 2013 4:30 pm Elan Provides Strategic Update - May 21st, 2013 1:46 pm Flush With Cash, Elan Goes on a Buying Spree - May 21st, 2013 11:44 am Elan Continues To Make Baffling Strategic Decision - May 21st, 2013 11:30 am Elan Proposes Sweeping Transformation - May 21st, 2013 5:10 am Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray - May 21st, 2013 5:07 am Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trials - May 20th, 2013 2:10 pm View All Current Headlines >>